Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-ranging study of PF-04937319 versus placebo, with sitagliptin comparator, in adults with type 2 diabetes inadequately controlled on metformin
2011-004002-25Phase 2Completed
- Sponsor
- Pfizer
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nerigliatin, sitagliptin and metformin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Pfizer. Primary endpoint: Change from baseline in HbA1c at Day 84. Started Nov 2011; status: completed.
02
Drugs
nerigliatinsitagliptinmetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2011-004002-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004002-25.